Forschergruppe Diabetes e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764, Munich, Germany.
Internal Medicine Department, Clinical County Emergency Hospital Constanta, Tomis Blvd. No. 145, 900591, Constanța, Romania.
Cardiovasc Diabetol. 2019 Mar 11;18(1):30. doi: 10.1186/s12933-019-0822-4.
The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25-26 October 2018. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CARMELINA, DECLARE-TIMI 58 and Harmony Outcomes. Trial implications for diabetes management and the impact of the new ADA/EASD consensus statement treatment algorithm were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for adjunct therapy of type 1 diabetes and, on the occasion of the 10 year anniversary of the FDA's "Guidance for Industry: "should CVOTs be continued and/or modified?" The 5th Cardiovascular Outcome Trial Summit will be held in Munich on 24-25 October 2019 ( http://www.cvot.org ).
第四届心血管结局试验（CVOT）峰会是糖尿病和心血管疾病（D＆CVD）EASD 研究小组于 2018 年 10 月 25 日至 26 日在慕尼黑举行的。与往年一样，本次峰会是深入讨论最近完成和提出的 CVOT 主题的参考会议。今年的重点是 CARMELINA、DECLARE-TIMI 58 和 Harmony Outcomes 这三项 CVOT。对于糖尿病专家、心脏病专家、内分泌专家、肾病专家和全科医生来说，试验对糖尿病管理的影响以及新的 ADA/EASD 共识治疗算法的影响被强调。从 CVOT 讨论到心力衰竭的其他治疗选择（ARNI），从 1 型糖尿病辅助治疗中获得的知识，以及在 FDA 发布“行业指南：是否应该继续和/或修改 CVOT？”十周年之际，会议都进行了讨论。第五届心血管结局试验峰会将于 2019 年 10 月 24 日至 25 日在慕尼黑举行（http://www.cvot.org）。
